| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Wagner Charles F Jr, EVP, CO & FO
Sold 15,286 shares ($8.37M) |
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | 144 |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 144 |
| 10 Nov 2026 |
Form 4: Kewalramani Reshma, Director
Sold 11,866 shares ($6.31M) |
| 06 Nov 2026 | 144 |
| 03 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
— Achieved total revenue of $3.44 billion, a 12% increase compared to third quarter 2025 — |
| 22 Oct 2026 |
Form 4: Brennan Daniel J., Director
Received 795 shares as a grant or award ($400K) |
| 22 Oct 2026 |
Form 3: Brennan Daniel J., Director
No securities owned |
| 20 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”). In connection with the appointment of Mr. Brennan, the size of the Boar... |
| 19 Oct 2026 |
Form 4: Sachs Bruce I, Director
Granted 92.694 Deferred Stock Units ($47.5K) |
| 19 Oct 2026 |
Form 4: Garber Alan M, Director
Granted 29.272 Deferred Stock Units ($15K) |
| 10 Sep 2026 |
Form 4: van Grunsven Jasper, EVP, CP and NPPO
Received 8,682 shares as a grant or award |
| 10 Sep 2026 |
Form 3: van Grunsven Jasper, EVP, CP and NPPO
No securities owned |
| 01 Sep 2026 |
Form 4: Ambrose Kristen, SVP & Chief Accounting Officer
Received 5,000 shares as a grant or award |
| 01 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”). In connection with... |
| 31 Aug 2026 |
Form 4: Sachs Bruce I, Director
Gave 6,000 shares as a gift |
| 27 Aug 2026 | 144 |
Loading...